Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update

Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update

Abstract: The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group conducted the SAKK 35/10 randomized phase 2 trial to compare rituximab (R) alone vs R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1 to 3A FL, requiring systemi...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Kimby, Sämi Schär, Maria Cristina Pirosa, Anna Vanazzi, Ulrich M. Mey, Daniel Rauch, Björn E. Wahlin, Felicitas Hitz, Micaela Hernberg, Ann-Sofie Johansson, Peter de Nully Brown, Hans Hagberg, Andrés José María Ferreri, Fatime Krasniqi, Michèle Voegeli, Urban Novak, Thilo Zander, Hanne Bersvendsen, Christoph Mamot, Walter Mingrone, Anastasios Stathis, Stefan Dirnhofer, Stefanie Hayoz, Bjørn Østenstad, Emanuele Zucca
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925000618
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925000618

Similar Items